|
|
|
|
|
terug |
Datum nieuwsfeit: 21-07-2004
Dendrite rondt strategische overname Schwarzeck-Verlag af
( BW)(NJ-DENDRITE)(DRTE) Dendrite Completes Strategic Acquisition of
Schwarzeck-Verlag GmbH; Dendrite's German Presence Strengthened by
Expanded Solution Offerings and Larger Customer Base
Business Editors
MORRISTOWN, N.J.--(BUSINESS WIRE)--July 20, 2004--Dendrite
International, Inc. (NASDAQ: DRTE) today announced the completion of
its strategic acquisition of Schwarzeck-Verlag GmbH. A subsidiary of
Deutscher Aerzte Verlag GmbH based in Munich, Schwarzeck is a leading
provider of physician databases, direct marketing services, and sample
fulfillment services to pharmaceutical companies in Germany.
The acquisition accelerates Dendrite's expansion in Europe and
extends its interactive marketing solutions and services to the German
pharmaceutical industry. It creates one of the most diversified
German-based suppliers of pharmaceutical-specific services, data, and
technology to drug manufacturers in one of the world's largest
pharmaceutical markets. By combining Dendrite's sales support
solutions with Schwarzeck's marketing support services, the
acquisition provides customers with a comprehensive, integrated array
of offerings from a single supplier.
"Like our recent purchase of Medical Data Management, our
acquisition of Schwarzeck reflects our continued commitment to meet
the growing needs of our European customers," said Dendrite President
and COO Paul Zaffaroni. "The merger of our two companies not only
gives Dendrite a more substantial presence in Germany, but it also
provides customers with enhanced solutions for maximizing their
promotional initiatives."
Schwarzeck Managing Director Harald Finger added, "Pharmaceutical
companies in the region are increasingly partnering with only those
vendors that offer a strong combination of technology, support,
industry expertise, and local market knowledge. By joining forces with
Dendrite, we believe we have a comprehensive portfolio of sales and
marketing solutions that will be attractive to the German
pharmaceutical industry."
Key Acquisition Elements
Completed on July 13, 2004, the Schwarzeck acquisition provides a
compelling value proposition that includes:
-- Comprehensive Database Services
Dendrite will add Schwarzeck's physician information sources to
its own Pharbase(TM) database services to provide pharmaceutical
clients in Germany with one of Europe's richest sources of customer
information from which to align sales resources, target and segment
customers, conduct sales and marketing initiatives, and measure
program results.
-- New Interactive Marketing and Fulfillment Services
Pharmaceutical companies in Germany can now benefit from a broad
range of direct marketing services--including sample fulfillment,
direct mail, and printing services--delivered in a cost-effective and
efficient integrated manner by a single provider.
-- Senior Leadership and Expertise
Founded in 1972 and employing more than 35 personnel, Schwarzeck
brings strong market leadership and experience to complement
Dendrite's industry expertise, providing customers with expert
guidance, support, and consultancy capabilities.
-- Access to New Customers
The Schwarzeck acquisition gives Dendrite a number of new clients
in one of the world's largest pharmaceutical markets. Schwarzeck
currently serves many of the top pharmaceutical companies in Germany.
Dendrite indicated that in 2003, Schwarzeck reported approximately
$4 million in revenue, excluding postage pass-through. Through
synergies created by its increased scale and local presence, Dendrite
expects the acquisition to be neutral to earnings for the remainder of
2004 and approximately $0.01 accretive in 2005. The transaction,
including the assumption of liabilities, is valued at approximately $1
million.
About Schwarzeck-Verlag GmbH
Based in Munich, Schwarzeck-Verlag GmbH (Schwarzeck) is a leading
provider of physician databases, interactive marketing, and
fulfillment services to the German pharmaceutical industry. For more
information, visit www.schwarzeck.de.
About Dendrite
Dendrite develops and delivers solutions that increase the
productivity of sales, marketing, and clinical processes for
pharmaceutical and other life sciences client. For more information,
visit www.dendrite.com.
Note: Dendrite is a registered trademark of Dendrite
International, Inc.
The foregoing contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. The
statements may be identified by such forward-looking terminology as
"expect," "believe," "may," "will," "intend," "plan," and similar
statements or variations. All "outlook" information constitutes
forward-looking statements. Such forward-looking statements are based
on our current expectations, estimates, assumptions and projections
and involve certain significant risks and uncertainties, including
those which may result from our dependence on the pharmaceutical
industry; dependence on major customers; economic pressures and
legislative and regulatory impact on our customers; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles for
our products; our fixed expenses in relation to fluctuating revenues;
successful and timely development and introduction of new products and
versions; rapid technological changes; increased competition;
international operations; acquisitions; our ability to attract and
retain key personnel; the protection of our proprietary technology;
our ability to compete in the Internet-related products and services
market; the continued demand for Internet-related products and
services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships with
third-party vendors; results from strategic relationships; risks
associated with events that may affect the world economy, including
terrorism, military action in the Middle East or threat of other
hostilities in the Middle East, Asia and other geographical regions;
catastrophic events which could negatively affect our information
technology infrastructure; difficulties disposing of certain of our
facilities; and unexpected changes in accounting regulations,
standards or interpretations. Other important factors that should be
considered are included in the Company's 10-K, 10-Qs, and other
reports filed with the SEC. Actual results may differ materially. The
Company assumes no obligation for updating any such forward-looking
statements to reflect actual results, changes in assumptions or other
changes affecting such forward-looking statements.
--30--KB/ny*
CONTACT: Dendrite International, Inc.
Erik Kopp, 908-541-5850
erik.kopp@dendrite.com